Back to top
more

CoDiagnostics (CODX)

(Delayed Data from NSDQ)

$1.16 USD

1.16
216,750

+0.02 (1.75%)

Updated Apr 18, 2024 03:59 PM ET

After-Market: $1.18 +0.02 (1.72%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Elevance Health (ELV) Beats Q1 Earnings Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 0.95% and 0.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.17% and 73.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sharecare, Inc. (SHCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sharecare, Inc. (SHCR) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ModivCare (MODV) Misses Q1 Earnings Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of -4.05% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DocGo Inc. (DCGO) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

DocGo Inc. (DCGO) delivered earnings and revenue surprises of 120% and 4.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 33.33% and 24.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -166.67% and 75.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Do Options Traders Know Something About CoDiagnostics (CODX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to CoDiagnostics (CODX) stock based on the movements in the options market lately.

CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) Q4 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Assure Holdings Corp. (IONM): Can Its 7.3% Jump Turn into More Strength?

by Zacks Equity Research

Assure Holdings Corp. (IONM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Should Value Investors Buy These Medical Stocks?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Has CoDiagnostics, Inc. (CODX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CoDiagnostics, Inc. (CODX) and Cronos Group (CRON) have performed compared to their sector so far this year.

Select Medical's (SEM) Rising Stake in Concentra to Aid

by Zacks Equity Research

Select Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million.

Trina Mukherjee headshot

Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks

by Trina Mukherjee

With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.